Literature DB >> 32418485

Cardiac magnetic resonance in patients with muscular dystrophies.

Chrysanthos Grigoratos1, Alberto Aimo2, Andrea Barison1,2, Vincenzo Castiglione2, Giancarlo Todiere1, Giulia Ricci3, Gabriele Siciliano3, Michele Emdin1,2.   

Abstract

Muscular dystrophies are inherited disorders sharing similar clinical features and dystrophic changes on muscle biopsy. Duchenne muscular dystrophy is the most common inherited muscle disease of childhood, and Becker muscular dystrophy is a milder allelic variant with a slightly lower prevalence. Myotonic dystrophy is the most frequent form in adults. Cardiac magnetic resonance is the gold standard technique for the quantification of cardiac chamber volumes and function, and also enables a characterisation of myocardial tissue. Most cardiac magnetic resonance studies in the setting of muscular dystrophy were carried out at single centres, evaluated small numbers of patients and used widely heterogeneous protocols. Even more importantly, those studies analysed more or less extensively the patterns of cardiac involvement, but usually did not try to establish the added value of cardiac magnetic resonance to standard echocardiography, the evolution of cardiac disease over time and the prognostic significance of cardiac magnetic resonance findings. As a result, the large and heterogeneous amount of information on cardiac involvement in muscular dystrophies cannot easily be translated into recommendations on the optimal use of cardiac magnetic resonance. In this review, whose targets are cardiologists and neurologists who manage patients with muscular dystrophy, we try to summarise cardiac magnetic resonance findings in patients with muscular dystrophy, and the results of studies evaluating the role of cardiac magnetic resonance as a tool for diagnosis, risk stratification and follow-up. Finally, we provide some practical recommendations about the need and timing of cardiac magnetic resonance examination for the management of patients with muscular dystrophy. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac magnetic resonance; Duchenne/Becker muscular dystrophy; diagnosis; follow-up; muscular dystrophy; myotonic dystrophy; risk stratification

Mesh:

Year:  2021        PMID: 32418485     DOI: 10.1177/2047487320923052

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  3 in total

1.  When Ejection Fraction Is Not Enough: The Search for Early Signs of Cardiomyopathy in Duchenne Muscular Dystrophy.

Authors:  Pierangelo Renella; Wyman W Lai
Journal:  Circ Cardiovasc Imaging       Date:  2020-11-16       Impact factor: 7.792

Review 2.  Pirfenidone as a novel cardiac protective treatment.

Authors:  Alberto Aimo; Giosafat Spitaleri; Giorgia Panichella; Josep Lupón; Michele Emdin; Antoni Bayes-Genis
Journal:  Heart Fail Rev       Date:  2021-10-20       Impact factor: 4.214

Review 3.  Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond.

Authors:  Alberto Aimo; Giosafat Spitaleri; Dario Nieri; Laura Maria Tavanti; Claudia Meschi; Giorgia Panichella; Josep Lupón; Francesco Pistelli; Laura Carrozzi; Antoni Bayes-Genis; Michele Emdin
Journal:  Card Fail Rev       Date:  2022-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.